加载中
NASDAQHealthcareBiotechnology
最新数据
US$10.92
−US$0.37 · -3.28%
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
收盘时
US$10.92
−US$0.37 · -3.28%
盘后
US$10.85
−US$0.07 · -0.64%
10月13日 16:33 ET
盘中时间采用ET。市场数据可能有所延迟。
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
日内区间
当前US$10.92
52周区间
当前US$10.92
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
54
合理估值
情绪
41
多空交织
风险
53
风险偏高
动量
60
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
日内区间
当前US$10.92
52周区间
当前US$10.92
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（AUD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 12.05亿 AUD | 7.83亿 AUD | 5.03亿 AUD | 1.6亿 AUD | 759.6万 AUD |
| 销货成本 | 5.65亿 AUD | 2.74亿 AUD | 1.88亿 AUD | 6517万 AUD | 3868.22万 AUD |
| 毛利 | 6.4亿 AUD | 5.1亿 AUD | 3.14亿 AUD | 9492.6万 AUD | 504.8万 AUD |
| 研究与开发 | 2.57亿 AUD | 1.21亿 AUD | 1.29亿 AUD | 5785.7万 AUD | 3413.5万 AUD |
| 销售、一般及管理费用 | 3.57亿 AUD | 2.07亿 AUD | 1.34亿 AUD | 8709.8万 AUD | 4698.6万 AUD |
| 营业费用 | 6.14亿 AUD | 4.28亿 AUD | 2.63亿 AUD | 1.87亿 AUD | 5330.26万 AUD |
| 利息收入 | 873.71万 AUD | 1086.2万 AUD | 67.1万 AUD | 1000 AUD | — |
| 利息支出 | 5506.34万 AUD | 2146.4万 AUD | 894.3万 AUD | 40.6万 AUD | 19.57万 AUD |
| 折旧和摊销 | 3266.58万 AUD | 802.68万 AUD | 674.3万 AUD | 537.9万 AUD | 517.4万 AUD |
| 营业利润 | 2664.17万 AUD | 8213万 AUD | 1584万 AUD | −9193万 AUD | −8124.7万 AUD |
| 净利润 | −1068.52万 AUD | 4991.9万 AUD | 521.1万 AUD | −1.04亿 AUD | −8051万 AUD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$18.00
上涨空间 64.84%报告持有此股票敞口的交易所交易基金。
Schwab International Equity ETFSCHF1865.28万0.03%673.48亿 USD0.03%US$27.14+0.04%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1052.71万0.03%406.96亿 USD0.03%US$49.78+0.19%
Schwab Fundamental International Small Company Index ETFFNDC522.43万0.17%30.68亿 USD0.39%US$49.74+0.48%
John Hancock Investments - Multifactor Developed International ETFJHMD94.74万0.10%9.86亿 USD0.39%US$44.30+0.61%
State Street SPDR Portfolio Europe ETFSPEU35.64万0.05%6.89亿 USD0.07%US$53.35+0.62%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA25.63万0.03%10.17亿 USD0.30%US$97.99+0.48%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX21.59万0.04%4.88亿 USD0.20%US$53.34+0.41%
ActivePassive International Equity ETFAPIE13.23万0.01%11.36亿 USD0.45%US$38.63+0.60%Schwab International Equity ETFSCHFState Street SPDR Portfolio Developed World ex-US ETFSPDWSchwab Fundamental International Small Company Index ETFFNDCJohn Hancock Investments - Multifactor Developed International ETFJHMDState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXActivePassive International Equity ETFAPIEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
